Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Voltaren Gel Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 475-C

    Initial Prior Authorization with Quantity Limit Voltaren Gel

    Customize your policy alerts

    Sign up for cvs_caremark Policy 475-C alerts

    Get alerted when Policy 475-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization, including quantity limits, for diclofenac sodium topical gel 1% and Voltaren Gel OTC. Coverage applies to osteoarthritis pain in joints amenable to topical treatment when specified clinical criteria are met.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Voltaren Gel
    Policy CodePolicy 475-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request documenting an amenable osteoarthritis treatment site and intolerance or contraindication to oral NSAIDs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 monthsInitial approval duration
    36 monthsContinuation approval duration
    1,000 g / 25 daysOne-month quantity limit
    3,000 g / 75 daysThree-month quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Qualifying pathways

    Coverage Criteria Overview

    Initial Therapy Criteria

    Authorization may be granted when the patient has osteoarthritis pain in a joint amenable to topical treatment and ONE of the following criteria is met.

    Initial therapy

    • Oral NSAID-related criterion

      • Intolerance: Treatment with the requested drug is necessary due to a concern about intolerance to oral NSAIDs.
      • Contraindication: Treatment with the requested drug is necessary due to a contraindication to oral NSAIDs.

    Continuation Therapy Criteria

    Continuation authorization may be granted when ALL of the following criteria are met.

    Continuation therapy

    • Positive clinical response: The patient has achieved or maintained a positive clinical response to the requested drug.
    • Periodic re-evaluation: The patient has been re-evaluated periodically to determine if treatment is still necessary.

    Diclofenac sodium topical gel 1% has not been evaluated for use on the spine, hip, or shoulder.

    Authorization and Coverage Risks

    Prior Authorization

    Submit initial prior authorization request

    Submit a prior authorization request for osteoarthritis pain in a joint amenable to topical treatment, such as the feet, ankles, knees, hands, wrists, or elbows. Establish that treatment with the requested drug is necessary due to either intolerance to oral NSAIDs or a contraindication to oral NSAIDs.

    • Document the affected joint and osteoarthritis pain.
    • Document concern about intolerance to oral NSAIDs or a contraindication to oral NSAIDs.
    Documentation Required

    Document response for continuation

    For continuation authorization, establish that the patient has achieved or maintained a positive clinical response to the requested drug and has been re-evaluated periodically to determine whether treatment remains necessary.

    • Document the positive clinical response.

    Product and Clinical Background

    Diclofenac sodium topical gel 1% is indicated for relief of osteoarthritis pain in joints amenable to topical treatment, such as the knees and joints of the hands.

    Products Referenced

    Products referenced by this document
    Generic productDiclofenac sodium topical gel 1%
    Brand productNo brand name listed; diclofenac sodium is identified as the generic name
    OTC productVoltaren Gel (OTC), diclofenac sodium topical gel 1%
    Dosage form and strengthTopical gel 1%

    Initial Therapy for Osteoarthritis Pain

    Initial Therapy for Osteoarthritis Pain

    Authorization may be granted when the patient has osteoarthritis pain in a joint amenable to topical treatment and ONE of the following criteria is met.

    Initial therapy

    • Qualifying pathway

      • Intolerance to oral NSAIDs: Treatment with the requested drug is necessary due to a concern about intolerance to oral NSAIDs.
      • Contraindication to oral NSAIDs: Treatment with the requested drug is necessary due to a contraindication to oral NSAIDs.

    Continuation Therapy

    Continuation Therapy

    Authorization may be granted when ALL of the following criteria are met.

    Continuation therapy

    • Positive clinical response: The patient has achieved or maintained a positive clinical response to the requested drug.
    • Periodic re-evaluation: The patient has been re-evaluated periodically to determine if treatment is still necessary.

    Quantity Limits by Product

    Quantity limits
    ProductDiclofenac sodium topical gel 1%
    One-month quantity limit1,000 grams per 25 days
    Fill-period applicationThe 25-day duration is used for a 30-day fill period to allow time for refill processing
    Quantity limits
    ProductDiclofenac sodium topical gel 1%
    Three-month quantity limit3,000 grams per 75 days
    Fill-period applicationThe 75-day duration is used for a 90-day fill period to allow time for refill processing
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Voltaren Gel
    Policy CodePolicy 475-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request documenting an amenable osteoarthritis treatment site and intolerance or contraindication to oral NSAIDs.
    SourceLink
    On This Page
    Coverage Criteria OverviewAuthorization and Coverage RisksProduct and Clinical BackgroundProducts ReferencedInitial Therapy for Osteoarthritis PainContinuation TherapyQuantity Limits by Product
  1. Document periodic re-evaluation of continued treatment necessity.
  2. Denial Risk

    Risk of denial if initial criteria are not met

    Initial authorization may be denied when the patient does not have osteoarthritis pain in a joint amenable to topical treatment or when neither oral NSAID intolerance nor an oral NSAID contraindication is established.

    • Qualifying joints include the feet, ankles, knees, hands, wrists, or elbows.
    • At least one oral NSAID-related criterion must be met: intolerance or contraindication.
    Denial Risk

    Risk of denial for continuation

    Continuation authorization may be denied when the patient has not achieved or maintained a positive clinical response to the requested drug or has not been periodically re-evaluated to determine whether treatment remains necessary.

    • Establish a positive clinical response.
    • Establish periodic re-evaluation of treatment necessity.
    Denial Risk

    Avoid untested treatment sites

    Use involving the spine, hip, or shoulder presents a coverage risk because diclofenac sodium topical gel 1% has not been evaluated for those sites.

    • Confirm that the requested treatment site is a joint amenable to topical treatment and is supported by the coverage criteria.
    Quantity limits
    ProductVoltaren Gel OTC (diclofenac sodium topical gel 1%)
    One-month quantity limit1,000 grams per 25 days
    Fill-period applicationThe 25-day duration is used for a 30-day fill period to allow time for refill processing
    Quantity limits
    ProductVoltaren Gel OTC (diclofenac sodium topical gel 1%)
    Three-month quantity limit3,000 grams per 75 days
    Fill-period applicationThe 75-day duration is used for a 90-day fill period to allow time for refill processing